Bausch Health Companies (BHC) Stock Rises on Q3 2026 Earnings

Bausch Health Companies (BHC) reported Q3 2026 revenue of $2.9B, up 52.75% YoY, with net income of $436M and EPS of $1.17. Cash from operations doubled to $814M, and shares rose 13.73% post-earnings. Insiders sold shares, while institutional investors had mixed activity.

Original reporting
Published Oct 29, 2026, 1:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bausch Health Companies (BHC) Stock Rises on Q3 2026 Earnings — source image
Decision brief

The 30-second read

$BHCBullishHigh
01

Why it matters

The earnings beat and strong cash flow drove a notable post‑market price jump, suggesting short‑term buying interest.

02

Market read

Earnings surprise creates immediate trading opportunity; sector peers may be impacted.

03

What to watch

High debt level ($25.8B) could limit long‑term upside despite earnings beat.

Relevance 8/10Novelty 9/10Timing: after-hours reaction

Background

Bausch Health Companies Inc. (BHC) released its Q3 2026 earnings, showing significant revenue and profit growth.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Bausch Health reported Q3 2026 revenue of $2.9B and EPS $1.17, driving a 13.73% share rise after hours.

Expected impact

potential upward pressure as traders price in the earnings beat

Evidence & confidence

Revenue and profit surged >50% YoY, EPS beat expectations, and the stock already jumped 13.7%.

Market effects

Improves outlook for the broader pharma/healthcare sector with strong earnings momentum.

Positive for North American healthcare stocks.

Limited to sector; no broad macro impact.

Counterpoint

The earnings surge may be unsustainable if growth slows; watch for guidance on future quarters.

Key entities

  • Bausch Health Companies Inc.

    Issuer of the earnings report.

Related articles

$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.